Key facts
- Palobiofarma’s last known valuation is $79.3M.
- It has raised $21.1M; the latest was Later Stage VC ($7.7M) in May 2024.
- Notable investors include European Union, INNVIERTE SICC, Inveready Asset Management, Sociedad de Desarrollo de Navarra, Agencia de Innovación — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Palobiofarma
- ·The full record, as it builds
Funding rounds
No funding rounds for Palobiofarma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Palobiofarma
Developer of adenosine receptor modulators designed to advance treatments for orphan and neurological diseases. The company offers virtual drug design, medicinal chemistry, in-vitro pharmacology expertise, and compound characterization capabilities, enabling biopharma researchers and healthcare providers to access targeted therapeutics with improved clinical potential.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2005
- Employees
- 20
- Website
- palobiofarma.com/
- Ownership
- Privately Held (backing)
Palobiofarma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Palobiofarma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Palobiofarma in its N-PORT filings yet. We sweep new filings monthly.